You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,366,728


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,366,728
Title: Stable forms of antigenic Taenia ovis polypeptides
Abstract:Stable forms of Taenia ovis peptide antigens, such as portions of a T. ovis oncosphere antigen which runs as a 47-52 kDa doublet, are suitable for use in vaccines to protect ruminants against infection by cestode parasites. The antigens are preferably obtained by isolation and expression of the DNA encoding them in recombinant host cells. Aspects of the invention include DNA encoding T. ovis antigens, vectors containing such DNA and host cells which express the T. ovis antigens.
Inventor(s): Harrison; Gavin B. L. (Upper Hutt, NZ), Dempster; Robert P. (Upper Hutt, NZ), Rickard; Michael D. (Werribee, AU), Lightowlers; Marshall W. (Victoria, AU), Heath; David D. (Paremata, NZ), Lawrence; Stephen B. (Upper Hutt, NZ), O\'Hoy; Kim L. (Pascoe Vale, AU)
Assignee: Pitman-Moore New Zealand Limited (Upper Hutt, NZ) The University of Melbourne (Melbourne, AU) Her Majestry the Queen in right of New Zealand through the Ministry of (Wellington, NZ)
Application Number:07/969,450
Patent Claims:1. A stable antigenic immunologically active protective peptide essentially free from naturally occurring admixtures, said peptide comprising a fragment of a T. ovis oncosphere antigen which runs as a 47-52 kDa doublet on SDS-PAGE, which fragment:

(a) has a molecular weight of from about 23 kDa to about 24 kDa; and

(b) generates a protective immunological response to T. ovis infection in a ruminant;

or a stable protective subfragment of said 23-24 kDa fragment which subfragment generates a protective immunological response to T. ovis infection.

2. A peptide as claimed in claim 1, comprising the amino acid sequence:

or a protective subfragment thereof, which subfragment generates a protective immunological response to T. ovis infection.

3. A peptide as claimed in claim 1 which is the product of expression of a nucleotide sequence coding therefor in a host cell.

4. A peptide as claimed in claim 3 which is expressed in the host cell as a fusion protein.

5. A peptide as claimed in claim 4 which is expressed as a fusion protein with the enzyme glutathione s-transferase.

6. A composition capable of generating a protective immunological response to T. ovis infection in a ruminant, said composition consisting essentially of a pharmaceutically acceptable adjuvant, carrier or diluent a component selected from the group consisting of:

(a) a protective peptide as claimed in claim 2,

(b) a stable immunologically active protective subfragment of a peptide as claimed in claim 2.

7. An isolated and essentially purified DNA molecule comprising a nucleotide sequence which encodes a purified stable protective antigenic peptide comprising a fragment of a T. ovis polypeptide antigen which runs as a 47-52 kDa doublet on SDS-PAGE which fragment:

(a) has a molecular weight of from about 23 kDa to about 24 kDa;

(b) generates a protective immunological response to T. ovis infection in a ruminant; or

which encodes a protective subfragment, said subfragment generating a protective immunological response to T. ovis infection.

8. An isolated and essentially purified DNA molecule which encodes an immunologically active protective peptide comprising a fragment of a T. ovis polypeptide which fragment is coded for by the nucleotide sequence

9. An isolated and essentially purified DNA molecule selected from the group consisting of:

(a) a nucleotide sequence encoding an immunologically active protective peptide as claimed in claim 2;

(b) a nucleotide sequence encoding a stable immunologically active protective subfragment of a peptide as claimed in claim 2.

10. An isolated and essentially purified DNA molecule comprising a 655 bp fragment of DNA as shown in FIG. 1 contained within E. coli transformant 45 W (ATCC accession number 67507) encoding a stable immunologically active protective peptide comprising a fragment of a polypeptide of T. ovis.

11. A DNA molecule as claimed in claim 7 which has been isolated from a natural source.

12. A DNA molecule as claimed in claim 7 which is intron-free.

13. A recombinant expression vector which contains a DNA molecule as claimed in claim 7.

14. A vector pGEX-2T-45W, consisting essentially of the Bam HI to Xho II fragment of T. ovis DNA as shown in FIG. 1.

15. A host cell transformed with a vector as claimed in claim 13 and capable of expressing the T. ovis peptide or fragment thereof which is encoded.

16. A host cell as claimed in claim 15 which is a prokaryote.

17. A host cell as claimed in claim 16, wherein the prokaryote host is E. coli.

18. A host cell as claimed in claim 17, wherein the prokaryote host is E. coli DH5.

19. A host cell as claimed in claim 15, which is a eukaryote.

20. A method of producing a stable antigenic immunologically active protective peptide essentially free from naturally occurring admixtures, said peptide comprising a fragment of a T. ovis oncosphere antigen which runs as a 47-52 kDa doublet on SDS-PAGE, which fragment has a molecular weight of from about 23 kDa to about 24 kDa and which generates a protective immunological response to T. ovis infection in a ruminant, or a stable protective subfragment of said 23-24 kDa fragment which subfragment generates a protective immunological response to T. ovis infection, said method comprising the steps of:

culturing a cell as claimed in claim 15, and

recovering the expressed peptide.

21. A method as claimed in claim 20, wherein the antigenic peptide is recovered in a soluble form.

22. A method as claimed in claim 20, wherein the antigenic peptide is recovered in an insoluble form and is subsequently solubilized.

23. A stable antigenic peptide comprising a fragment of the T. ovis polypeptide antigen which runs as a 47-52 kDa doublet on SDS-PAGE produced by the method of claim 20.

24. A vaccine comprising an immunologically-effective amount of a stable immunologically active protective peptide as claimed in claim 1 in combination with a pharmaceutically acceptable adjuvant, carrier or diluent therefor.

25. A method of protecting a ruminant against T. ovis infection, which method comprises the step of administering to a said ruminant a stable immunologically active protective peptide as claimed in claim 1 in an amount effective to generate in said ruminant a protective immunological response to T. ovis infection.

26. A method of protecting a ruminant against T. ovis infection, which method comprises the step of administering to a said ruminant a composition as claimed in claim 6 in an amount effective to generate in said ruminant a protective immunological response to T. ovis infection.

27. A method of protecting a ruminant against T. ovis infection, which method comprises the step of administering to a said ruminant a vaccine as claimed in claim 24 in an amount effective to generate in said ruminant a protective immunological response to T. ovis infection.

Details for Patent 5,366,728

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2008-01-06
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2008-01-06
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2008-01-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.